A Phase 1/2 Study of Pomalidomide, Dexamethasone and Pegylated Liposomal Doxorubicin for Patients With Relapsed/Refractory Multiple Myeloma
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 07 Mar 2018
At a glance
- Drugs Pomalidomide (Primary) ; Dexamethasone; Doxorubicin liposomal
- Indications Multiple myeloma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Biomira USA
- 08 Mar 2016 Planned End Date changed from 1 Feb 2016 to 1 Dec 2016, as reported by ClinicalTrials.gov.
- 08 Mar 2016 Planned primary completion date changed from 1 Oct 2015 to 1 Dec 2016, as reported by ClinicalTrials.gov.
- 08 Mar 2016 Status changed from recruiting to active, no longer recruiting, as reported by ClinicalTrials.gov.